James Edgemond - 15 Dec 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role: CFO AND TREASURER
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol: UTHR
Transactions as of: 15 Dec 2025
Net transactions value: -$1,228,605
Form type: 4
Filing time: 16 Dec 2025, 17:09:23 UTC
Previous filing: 09 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
EDGEMOND JAMES	CFO AND TREASURER	C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING	/s/ John S. Hess, Jr. under Power of Attorney	16 Dec 2025	0001636178

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	UTHR	Common Stock	Options Exercise	$513,588	+3,517	+43%	$146.03	11,659	15 Dec 2025	Direct	F1, F2
transaction	UTHR	Common Stock	Sale	$78,644	-160	-1.4%	$491.52	11,499	15 Dec 2025	Direct	F1, F3
transaction	UTHR	Common Stock	Sale	$413,958	-840	-7.3%	$492.81	10,659	15 Dec 2025	Direct	F1, F4
transaction	UTHR	Common Stock	Sale	$276,968	-561	-5.3%	$493.70	10,098	15 Dec 2025	Direct	F1, F5
transaction	UTHR	Common Stock	Sale	$178,206	-360	-3.6%	$495.02	9,738	15 Dec 2025	Direct	F1, F6
transaction	UTHR	Common Stock	Sale	$257,869	-520	-5.3%	$495.90	9,218	15 Dec 2025	Direct	F1, F7
transaction	UTHR	Common Stock	Sale	$99,395	-200	-2.2%	$496.97	9,018	15 Dec 2025	Direct	F1, F8
transaction	UTHR	Common Stock	Sale	$196,745	-395	-4.4%	$498.09	8,623	15 Dec 2025	Direct	F1, F9
transaction	UTHR	Common Stock	Sale	$119,835	-240	-2.8%	$499.31	8,383	15 Dec 2025	Direct	F1, F10
transaction	UTHR	Common Stock	Sale	$120,573	-241	-2.9%	$500.30	8,142	15 Dec 2025	Direct	F1, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	UTHR	Stock Option	Options Exercise	$0	-3,517	-100%	$0.000000	0	15 Dec 2025	Common Stock	3,517	$146.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.
F2	The amount of common stock beneficially owned by the Reporting Person in the Reporting Person's Form 4s filed November 5, 12 and 18, 2025 did not include 24 shares acquired by the Reporting Person on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan, which error caused the reporting person's common stock ownership to be underreported by 24 shares on such Form 4s. The amount of common stock beneficially owned by the Reporting Person in this Form 4 includes such shares.
F3	This transaction was executed in multiple trades at prices ranging from $491.19 to $491.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5	This transaction was executed in multiple trades at prices ranging from $493.35 to $494.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6	This transaction was executed in multiple trades at prices ranging from $494.52 to $495.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7	This transaction was executed in multiple trades at prices ranging from $495.52 to $496.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8	This transaction was executed in multiple trades at prices ranging from $496.59 to $497.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9	This transaction was executed in multiple trades at prices ranging from $497.60 to $498.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10	This transaction was executed in multiple trades at prices ranging from $498.88 to $499.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11	This transaction was executed in multiple trades at prices ranging from $499.92 to $500.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.